Home › Therapeutic areas › Oncology › Glioblastoma

Glioblastoma (18 companies)

Companies with an active program in Glioblastoma.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
DRTS Alpha Tau Medical Oncology 1 Phase 2 $1.12B 6
BDTX Black Diamond Therapeutics Oncology 1 Phase 2 $82.8M 4
CADL Candel Therapeutics Oncology 1 Phase 3 $424M 4
CLRB Cellectar Biosciences Oncology 1 Phase 2 $9.2M 7
CMPX Compass Therapeutics Oncology 1 Phase 2 $109M 15
FBIO Fortress Biotech DermatologyHematology+4 Rare 2 Approved $61.4M 16
IBRX ImmunityBio Infectious DiseaseOncology 2 Approved $6.66B 17
INAB IN8bio ImmunologyOncology 2 Phase 1 $8.9M 4
INBX Inhibrx Biosciences Oncology 1 NDA Submitted $1.10B 6
KAPA Kairos Pharma Oncology 1 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 3 Phase 2 $60.7M 13
MAIA MAIA Biotechnology Oncology 1 Phase 3 $77.2M 8
MDNAF Medicenna Therapeutics Oncology 1 Phase 2 $14.8M 10
MBRX Moleculin Biotech Oncology 3 Phase 2 $7.3M 9
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $660M 9
PYPD PolyPid Infectious DiseaseMetabolic+1 1 NDA Submitted $138M 4
TNGX Tango Therapeutics Oncology 1 Phase 1 $3.75B 5
TLX Telix Pharmaceuticals Oncology 3 Approved $3.01B 25